Related references
Note: Only part of the references are listed.Modulation of CD20 Antigen Expression After Rituximab Treatment: A Retrospective Study in Patients With Chronic Lymphocytic Leukemia
Fiorella D'Auria et al.
CLINICAL THERAPEUTICS (2010)
Down-regulation of CD20 expression in B-cell lymphoma cells after treatment with rituximab-containing combination chemotherapies: its prevalence and clinical significance
Junji Hiraga et al.
BLOOD (2009)
Diffuse large B-cell lymphoma: reduced CD20 expression is associated with an inferior survival
Nathalie A. Johnson et al.
BLOOD (2009)
Histological and immunophenotypic changes in 59 cases of B-cell non-Hodgkin's lymphoma after rituximab therapy
Akiko Miyagi Maeshima et al.
CANCER SCIENCE (2009)
Identification of CD20 C-Terminal Deletion Mutations Associated with Loss of CD20 Expression in Non-Hodgkin's Lymphoma
Yasuhito Terui et al.
CLINICAL CANCER RESEARCH (2009)
CD20 mutations involving the rituximab epitope are rare in diffuse large B-cell lymphomas and are not a significant cause of R-CHOP failure
Nathalie A. Johnson et al.
HAEMATOLOGICA-THE HEMATOLOGY JOURNAL (2009)
Acquirement of rituximab resistance in lymphoma cell lines is associated with both global CD20 gene and protein down-regulation regulated at the pretranscriptional and posttranscriptional levels
Myron S. Czuczman et al.
CLINICAL CANCER RESEARCH (2008)
Usefulness of flow cytometry for differential diagnosis of precursor and peripheral T-cell and NK-cell lymphomas: Analysis of 490 cases
Kennosuke Karube et al.
PATHOLOGY INTERNATIONAL (2008)
Epigenetic regulation of CD20 protein expression in a novel B-Cell lymphoma cell line, RRBL1, established from a patient treated repeatedly with rituximab-containing chemotherapy
Akihiro Tomita et al.
INTERNATIONAL JOURNAL OF HEMATOLOGY (2007)
Rituximab-CHOP versus CHOP alone or with maintenance rituximab in older patients with diffuse large B-cell lymphoma
Thomas M. Habermann et al.
JOURNAL OF CLINICAL ONCOLOGY (2006)
Analysis of changes in CD20, CD55, and CD59 expression on established rituximab-resistant B-lymphoma cell lines
K Takei et al.
LEUKEMIA RESEARCH (2006)
Immunohistochemical analysis of the antiapoptotic Mcl-1 and Bcl-2 proteins in follicular lymphoma
J Michels et al.
BRITISH JOURNAL OF HAEMATOLOGY (2006)
Prognostic significance of bcl-xL gene expression and apoptotic cell counts in follicular lymphoma
WL Zhao et al.
BLOOD (2004)
Rituximab (monoclonal anti-CD20 antibody): mechanisms of action and resistance
MR Smith
ONCOGENE (2003)
Alanine-170 and proline-172 are critical determinants for extracellular CD20 epitopes; heterogeneity in the fine specificity of CD20 monoclonal antibodies is defined by additional requirements imposed by both amino acid sequence and quaternary structure
MJ Polyak et al.
BLOOD (2002)
CHOP chemotherapy plus rituximab compared with CHOP alone in elderly patients with diffuse large-B-cell lymphoma.
B Coiffier et al.
NEW ENGLAND JOURNAL OF MEDICINE (2002)
CD20 levels determine the in vitro susceptibility to rituximab and complement of B-cell chronic lymphocytic leukemia: further regulation by CD55 and CD59
J Golay et al.
BLOOD (2001)
Share Paper
